Literature DB >> 7192957

Pharmacokinetics of high-dose meperidine in surgical patients.

A J Koska, W G Kramer, A Romagnoli, A S Keats, P B Sabawala.   

Abstract

Intravenous meperidine is used during surgical procedures at doses up to 5 mg/kg. At the commonly used analgesic intravenous doses of 50 to 100 mg (0.7 to 1.4 mg/kg), the drug exhibits two-compartment open model pharmacokinetics with elimination primarily by hepatic metabolism (> 90% of a dose). Drugs eliminated to a large extent by metabolism may, however, be subject to dose-dependent kinetics. We therefore studied the pharmacokinetics of surgery involving the lower part of the abdominal aorta and the femoral and popliteal arteries. Serial blood samples were collected over 10 hours and plasma meperidine concentrations were determined by a gas chromatographic assay. Semilogarithmic plots of plasma meperidine concentration vs time were biphasic; however, the curves' irregularities during the time the arterial vessels were clamped suggest that the data should be analyzed in a model-independent manner. These irregularities suggest that the disposition of meperidine is altered during the clamping period and that these alterations are quickly reversed following removal of the clamp. Our findings agree with those reported in the literature following a total dose of 50 mg (half-life average 4.4 hours, total plasma clearance 10.4 ml/min/kg, and apparent volume of distribution 3.74 L/kg). The present results thus indicate that although meperidine is eliminated to a large extent by metabolism, the processes involved are apparently not saturated at doses 7 times greater than normal.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7192957

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Patient posture and the anaesthetist.

Authors:  T E Healy; R G Wilkins
Journal:  Ann R Coll Surg Engl       Date:  1984-01       Impact factor: 1.891

Review 3.  Clinical pharmacokinetics of pethidine: 1982.

Authors:  D J Edwards; C K Svensson; J P Visco; D Lalka
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

4.  Effects of opioids on human serotonin transporters.

Authors:  M Barann; U M Stamer; M Lyutenska; F Stüber; H Bönisch; B Urban
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-22       Impact factor: 3.000

Review 5.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

6.  Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 7.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.